IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i1p65-71.html
   My bibliography  Save this article

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Author

Listed:
  • Valentin Brodszky
  • Petra Baji
  • Orsolya Balogh
  • Márta Péntek

Abstract

The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European countries. This paper presents the estimated budget impact of the introduction of biosimilar infliximab in RA over a 3-year time period in six selected countries, namely Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. A prevalence-based model was constructed for budget impact analysis. Two scenarios were compared to the reference scenario (RSc) where no biosimilar infliximab is available: biosimilar scenario 1 (BSc1), where interchanging the originator infliximab with biosimilar infliximab is disallowed, and only patients who start new biological therapy are allowed to use biosimilar infliximab; as well as biosimilar scenario 2 (BSc2), where interchanging the originator infliximab with biosimilar infliximab is allowed, and 80 % of patients treated with originator infliximab are interchanged to biosimilar infliximab. Compared to the RSc, the net savings are estimated to be €15.3 or €20.8 M in BSc1 and BSc2, respectively, over the 3 years. If budget savings were spent on reimbursement of additional biosimilar infliximab treatment, approximately 1,200 or 1,800 more patients could be treated in the six countries within 3 years in the two biosimilar scenarios, respectively. The actual saving is most sensitive to the assumption of the acquisition cost of the biosimilar drug and to the initial number of patients treated with biological therapy. The study focused on one indication (RA) and demonstrated that the introduction of biosimilar infliximab can lead to substantial budget savings in health care budgets. Further savings are expected for other indications where biosimilar medicines are implemented. Copyright Springer-Verlag Berlin Heidelberg 2014

Suggested Citation

  • Valentin Brodszky & Petra Baji & Orsolya Balogh & Márta Péntek, 2014. "Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 65-71, May.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:65-71
    DOI: 10.1007/s10198-014-0595-3
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-014-0595-3
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-014-0595-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Katelijne Vooren & Silvy Duranti & Alessandro Curto & Livio Garattini, 2014. "A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries," Applied Health Economics and Health Policy, Springer, vol. 12(1), pages 33-40, February.
    2. P. Laires & F. Exposto & R. Mesquita & A. Martins & L. Cunha-Miranda & J. Fonseca, 2013. "Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 875-885, December.
    3. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    4. Lászlo Tóthfalusi & László Endrényi & Shein-Chung Chow, 2014. "Statistical and regulatory considerations in assessments of interchangeability of biological drug products," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 5-11, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. László Gulácsi, 2014. "Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 1-4, May.
    2. Joost W. Geenen & Svetlana V. Belitser & Rick A. Vreman & Martijn Bloois & Olaf H. Klungel & Cornelis Boersma & Anke M. Hövels, 2020. "A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 845-853, August.
    3. Joost W. Geenen & Cornelis Boersma & Olaf H. Klungel & Anke M. Hövels, 2019. "Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 857-867, August.
    4. Nathalie Vernaz & François Girardin & Nicolas Goossens & Urs Brügger & Marco Riguzzi & Arnaud Perrier & Francesco Negro, 2016. "Drug Pricing Evolution in Hepatitis C," PLOS ONE, Public Library of Science, vol. 11(6), pages 1-12, June.
    5. Natalie Carvalho & Mark Jit & Sarah Cox & Joanne Yoong & Raymond C. W. Hutubessy, 2018. "Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Frame," PharmacoEconomics, Springer, vol. 36(1), pages 79-90, January.
    6. Josephine Mauskopf & Stephanie Earnshaw, 2016. "A Methodological Review of US Budget-Impact Models for New Drugs," PharmacoEconomics, Springer, vol. 34(11), pages 1111-1131, November.
    7. Zsombor Zrubka & Zsuzsanna Beretzky & Zoltán Hermann & Valentin Brodszky & László Gulácsi & Fanni Rencz & Petra Baji & Dominik Golicki & Valentina Prevolnik-Rupel & Márta Péntek, 2019. "A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 119-132, June.
    8. Petra Baji & Márta Péntek & Sándor Szántó & Pál Géher & László Gulácsi & Orsolya Balogh & Valentin Brodszky, 2014. "Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 45-52, May.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:65-71. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.